Browsing Tag
Protagonist Therapeutics Inc.
2 posts
Takeda’s MIMRYLO approval unlocks $275m for Protagonist and a $1bn-plus PV bet
Takeda has secured FDA approval for MIMRYLO in adults with polycythemia vera, triggering $275 million of payments to Protagonist Therapeutics and opening a launch Takeda believes could ultimately generate $1 billion to $2 billion in peak global sales.
Does Priority Review signal a commercial breakthrough for Protagonist Therapeutics, Inc.?
Takeda and Protagonist secure FDA Priority Review for rusfertide in PV. Explore the strategic, financial, and competitive implications now.